Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current Deferred Tax LiabilityNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Caribou Biosciences (CRBU) Operating Leases (2022 - 2025)

Caribou Biosciences (CRBU) has disclosed Operating Leases for 4 consecutive years, with $27.2 million as the latest value for Q4 2025.

  • Quarterly Operating Leases rose 8.64% to $27.2 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $27.2 million through Dec 2025, up 8.64% year-over-year, with the annual reading at $27.2 million for FY2025, 8.64% up from the prior year.
  • Operating Leases for Q4 2025 was $27.2 million at Caribou Biosciences, up from $22.8 million in the prior quarter.
  • The five-year high for Operating Leases was $27.9 million in Q3 2022, with the low at $22.8 million in Q3 2025.
  • Average Operating Leases over 4 years is $26.1 million, with a median of $26.5 million recorded in 2023.
  • Peak annual rise in Operating Leases hit 8.64% in 2025, while the deepest fall reached 14.5% in 2025.
  • Over 4 years, Operating Leases stood at $26.8 million in 2022, then fell by 3.26% to $25.9 million in 2023, then fell by 3.27% to $25.1 million in 2024, then increased by 8.64% to $27.2 million in 2025.
  • According to Business Quant data, Operating Leases over the past three periods came in at $27.2 million, $22.8 million, and $23.6 million for Q4 2025, Q3 2025, and Q2 2025 respectively.